Hepatic encephalopathy is an alteration of the central nervous system as a result of hepatic insufficiency after the exclusion of other known causes, and occurs in patients with cirrhosis, acute hepatic failure or portacaval shunts. 1 It is characterized by a range of different neuropsychiatric disturbances that can include impairment of the sleep-wake cycle, cognition, memory, consciousness, personality changes, motorsensory abnormalities, stupor and coma. 1 Minimal hepatic encephalopathy (MHE) is considered to be the first stage of this clinical course. It is defined as HE without symptoms on clinical/neurological examination but with mild cognitive symptoms and attention deficits that can be characterized by response disinhibition, and with impairments to working memory and visuomotor coordination. [2] [3] [4] As suggested by Bajaj, et al., these symptoms are considered to reduce the safety 2 and quality of life (QOL) of patients with cirrhosis 3 and are considered to be a preclinical stage of overt HE. 2, 3 MHE has a high prevalence of 22 to 80% in patients with liver cirrhosis. 2, 4 It is a diagnosis that all physicians should be aware of, but there is a fine line between normal and pathological, which can be modified by factors such as education or other comorbidities. At present, many questions remain regarding patients with MHE. Should they receive treatment? What type of treatment should they receive? How long should they receive treatment? Are there preventive measures for these patients?
With regard to the first question, several studies have shown a positive effect of treatment on cognitive abilities (Figure 1) , quality of life, 5 and driving ability (Figure 2) , 6 but its effect on patients' ability to work or their risk of falling remains unproven. 4 A summary of reports of treatment in MHE and its impact on psychometric variables is presented in table 1, which suggests that treatment should be considered.
The next question that arises is the type of treatment that patients with MHE should receive. Many approaches have been proposed, including lactulose, rifaximin and probiotics, minimizing dietary protein, branched-chain amino acids, 7 and L-ornithine L-aspartate (LOLA). 5 Nonabsorbable disaccharides reduce the synthesis and uptake of ammonia by lowering the pH of the colon and also reduce the uptake of glutamine from the gut. 4 Treatment of MHE with lactulose resulted in an absolute risk reduction of 21.7% and the number needed to treat was 4.6. Different studies have compared the use of lactulose with placebo or no in- CI: -1.96 to -1.56, P < 0.00001). The usual oral dose of lactulose is 15-30 mL twice daily to achieve a soft stool several times a day. Even though different durations of treatment have been tested in different randomized clinical trials (RCT), we consider that a course of treatment should continue for at least 3 to 6 months.
Another approach for treatment of MHE is the use of antibiotics, which aims to reduce the production of ammonia in the gut. Neomycin and macrolides have been used, but because of their toxicity new drugs are under study. Rifaximin is an antibiotic that shows minimal absorption in the gut and has been licensed in the United States of America since 2010 for the treatment of HE. 4 Bass, et al. 9 were able to show in a large study that long-term therapy with rifaximin plus lactulose in patients with a history of HE gave better protection against renewed episodic HE than did the placebo treatment (hazard ratio with rifaximin: 0.42; 95% CI 0.28-0.64; P < 0.001). When the effects in patients with MHE were analyzed by Sidhu, et al., more patients showed remission of MHE after treatment for 8 weeks with a dose of 1,200 mg/day of rifaximin than in the placebo group (75.5 vs. 20%; P < 0.0001). 10 Probiotics have also been used in the treatment of HE. They reduce ammonia in the portal blood by decreasing bacterial urease activity in the intestinal lumen, decrease ammonia absorption by decreasing intestinal pH and improve the nutritional status of gut epithelium. Overall, these effects decrease intestinal permeability, inflammation and oxidative stress in hepatocytes, which leads to increased hepatic clearance of ammonia. 5 Yogurt has been proposed as a probiotic treatment as it is a palatable food, is widely available and does not require prescription, all of which favor long-term adherence to treatment. However, the reported studies used different concentrations of probiotics. Complete reversal of MHE was achieved only in those patients who consumed yogurt (71%, P = 0.003) and was associated with an improvement in psychometric test results. 5 In a random effects meta-analysis performed by Holte, et al., probiotics/synbiotics vs. placebo or lactulose improved HE (51 vs. 31%, RR = 1.40, 95% CI = 1.05-1.86; I2 = 5%, P = 0.02), so perhaps this line of treatment could have potential. 11 Finally, we consider the question of prophylaxis. Lactulose has been proposed for primary prophylaxis of MHE. 12 In the study by Sharma, et al. of 250 patients screened, 120 (48%) met the inclusion criteria and were randomized to lactulose (n = 60) or no lactulose (n = 60). Twenty (19%) of 105 patients followed for 12 months developed an episode of overt HE. Six (11%) of 60 in the lactulose group and 15 (28%) of 50 in the no lactulose group (P = 0.02) developed overt HE.
We conclude that in patients with MHE a course of treatment is warranted to improve their quality of life. We are conscious that more RCT and metaanalyses are needed to identify the optimal treatment, as some of the reported trials do not separate the treatment of MHE from treatment of all HE. Several treatment alternatives have been proposed (Table 2), from just a few days duration up to 3 or 6 months, and we consider that at least 6 months treatment with lactulose or probiotics should be initiated once a diagnosis has been made, and a course of lactulose as prophylaxis needs to be considered. In summary, we encourage new studies and novel rifaximin group: 13 ± 3; 8 ± 2 (P = 0.04) placebo group: 13 ± 4; 11 ± 3 (P = 0.45). Improved driving ability in the rifaximin group: reduction in total number of driving errors (P = 0.0001), times exceeding the speed limit (P = 0.006), and illegal turns (P = 0.03).
Increased interleukin-10 in the rifaximin group (P = 0.01).
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RCT Rifaximin (n = 49) RCT: randomized controlled trial. SIP: sickness impact profile (questionnaire assessing health-related quality of life; the lower the value, the better the quality of life). MHE: minimal hepatic encephalopathy. MELD: model for end-stage liver disease. CI: confidence interval. (n = 97) (OHE). approaches to this increasing pathology, though rigorous evaluation is still needed.
ABBREVIATIONS
• CI: confidence interval.
• HE: hepatic encephalopathy.
• LOLA: L-ornithine L-aspartate.
• MHE: minimal hepatic encephalopathy.
• QOL: quality of life.
• RCT: randomized clinical trials.
• RR: relative risk.
• WMD: weighted mean difference.
